

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 10, 2013

BIOAMBER INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-35905
(Commission
File Number)

98-0601045
(I.R.S. Employer
Identification No.)

1250 Rene Levesque West, Suite 4110
Montreal, Quebec, Canada H3B 4W8

3850 Lane North, Suite 180
Plymouth, Minnesota 55447

(Address of principal executive offices)

Registrant's telephone number, including area code (514) 844-8000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

BioAmber Inc. (the “Company”) announced today that on June 10, 2013, the French Autorité des marchés financiers approved the Company’s prospectus for admission of its common stock to listing and trading on the Professional Segment of NYSE Euronext Paris under the symbol “BIOA.” The Company’s common stock will commence trading on the NYSE Euronext Paris on June 11, 2013.

A copy of the Press Release issued by the Company announcing the separation of the units is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits**

<u>Exhibits Number</u>	<u>Description</u>
99.1	Press Release, dated June 10, 2013, issued by BioAmber Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 10, 2013

BIOAMBER INC.

By: /s/ Jean-François Huc

Jean-François Huc

President, Chief Executive Officer and Director

Exhibit Index

Exhibits
Number

Description

99.1 Press Release, dated June 10, 2013, issued by BioAmber Inc.



BioAmber Inc. Announces Admission to NYSE Euronext Paris

Minneapolis, MN, June 10, 2013 – BioAmber Inc. (“BioAmber”) (NYSE:BIOA) announced today that the French Autorité des marchés financiers (AMF) approved BioAmber’s prospectus for admission of its common stock to listing and trading on the Professional Segment of NYSE Euronext Paris, and has granted visa number 13-265, dated June 10, 2013, on the prospectus. The attention of investors is drawn to the risk factors described in the prospectus.

BioAmber’s common stock will commence trading on the NYSE Euronext Paris exchange on June 11, 2013 at 09:00 Central European Time under the symbol “BIOA,” and will be denominated in Euros on the Paris exchange.

A copy of the prospectus can be obtained free of charge from BioAmber Inc. by writing to the company at 1250 Rene Levesque West, Suite 4110, Montreal, Quebec, Canada H3B-4W8, or from the company website (www.bio-amber.com), or from its paying agent, BNP Paribas Securities Services (Postal address: 3, rue d’Antin, 75002, France), or from the AMF website (www.amf-france.org).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BioAmber Inc.

BioAmber is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products. For more information about BioAmber visit www.bio-amber.com

Forward-Looking Statements

This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact

Chad Rubin
The Trout Group, LLC
New York
740 Broadway
9th Floor
New York, NY 10003
Tel: +1 (646) 378-2947
Fax: +1 (646) 378-2901
crubin@troutgroup.com